Genetic Exploration of the Molecular Basis of Malignancy in Adults

Neoplasms Clinical Trial

— GEMMA  

Official title:

Genetic Exploration of the Molecular Basis of Malignancy in Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02416518
• Other study ID #: SH GEMMA
• Status: Completed
• Start date: May 2014
• Est. completion date: December 2018

Study information

• Verified date: April 2019
• Source: Sanford Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Genetic Exploration of the Molecular Basis of Malignancy in Adults.

Description:

This protocol is not designed as a treatment protocol. Patients enrolled on this study will be treated according to the treating physician's plan of care, independent of enrollment into the study. Once enrolled, the physician may proceed with the appropriate plan of care during the period of specimen analysis if indicated. Upon return of the results, therapy may or may not be altered based upon the patient's pathology, pertinent medical and treatment history, imaging studies, available clinical trials, and on the CLIA validated clinical molecular profiling results. Regardless of the results, the patient will be offered a treatment selected on an empirical basis by the treating physician at the individual site. All patients enrolled in the study will be followed for clinical outcome. Clinical molecular profiling results will expire 14 weeks following the date the Foundation One report is received. No investigational agents will be administered as part of this study. However, patients may be referred to open clinical trials based on the results of profiling. Patients referred for clinical trial may receive investigational agents under a separate clinical trial in accordance with the written protocol for which they are subsequently enrolled. All anti-neoplastic drugs used while participating in this study, whether used on-label or off-label, will be administered to the patient by the route of administration published in the FDA approved package insert. In addition, the dosing of the agent (including dose modifications) will be calculated based upon what is published in the FDA approved package insert.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: December 2018
• Est. primary completion date: March 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Understand and provide written informed consent and HIPAA Authorization prior to initiation of any study-specific procedures.

• Have a life expectancy of >3 months.

• Have a diagnosis of metastatic, incurable cancer and have progressed on at least one line of systemic therapy OR a cancer with no standard 1st-line systemic therapy shown to prolong survival (or where a clinical trial recommended as the 1st-line option). Patients do not have to be off-treatment when enrolled on this trial. However, please see section 6.4.8 regarding the required wash-out period before starting any FDA approved on-label or off-label treatment.

• Measurable disease (RECIST 1.1).

• Be =18 years of age.

• ECOG Performance status 0 or 1.

• In the opinion of the investigator, be medically suitable for and willing to undergo a biopsy or surgical procedure to obtain tissue as a part of routine care for their malignancy OR have adequate archival tissue from a previous biopsy, performed no more than 14 weeks prior to enrollment, available for profiling.

• Have adequate organ and bone marrow function as defined below: Bone marrow: absolute neutrophil count (ANC) = 1.5 x 109/L; hemoglobin = 9 g/dL; platelets >100 x 109/L Renal: creatinine clearance = 60 mL/min (calculated according to Cockcroft and Gault formula) or creatinine = 1.5 mg/dL Hepatic: bilirubin = 2.5 x the upper limit of normal (ULN); aspartate transaminases (AST/SGOT); alanine transaminases (ALT/SGPT) = 2.5 x ULN (or = 5 x ULN if due to underlying liver metastases)

• Female patients of childbearing potential must have a negative pregnancy test and agree to use at least two forms of contraception during the study and for at least one month after treatment discontinuation. For the purposes of this study, a female with child- bearing potential is defined as: any woman who meets the following criteria.

Has not undergone a hysterectomy or bilateral oophorectomy. Has not been naturally postmenopausal for at least 24 months (i.e. has had a menses at any time in the preceding 24 consecutive months).

• Male patients must use a form of barrier contraception that contains spermicide and is approved by the investigator / treating physician during the study and for at least one month after treatment discontinuation.

• No more than one prior screening attempt for SH GEMMA.

Exclusion Criteria:

• Have lesions that are not accessible to biopsy or not planned for biopsy as part of routine care OR if archival tissue will be used for profiling, an insufficient amount is available OR archival tissue was obtained = 14 weeks prior to enrollment.

• Have diagnosis of a hematologic malignancy.

• Diagnosis of astrocytoma, glioblastoma multiforme, or any other primary brain cancer.

• Have concurrent uncontrolled malignancy.

• Have symptomatic CNS metastasis. Patients with a history of CNS metastases who have been treated with whole brain irradiation must be stable without symptoms for 4 weeks after completion of treatment, with image documentation required, and must be either off steroids or on a stable dose of steroids for = 2 weeks prior to enrollment.

• Have uncontrolled concurrent illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmias, psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.

• Have known HIV, HBV, HCV infection.

• Previous enrollment in the SH GEMMA study. Patients are allowed one prior screening attempt.

• Are pregnant or breast-feeding patients or any patient with childbearing potential not using adequate contraception.

Related Conditions & MeSH terms

• Neoplasms

Locations

Country	Name	City	State
United States	Sanford Health	Bemidji	Minnesota
United States	Sanford Health	Bismarck	North Dakota
United States	Sanford Health	Fargo	North Dakota
United States	Sanford Health	Sioux Falls	South Dakota

Sponsors (1)

Lead Sponsor	Collaborator
Sanford Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility (proportion of patients with successful molecular profiling compared to the number of patients enrolled)	Assess the feasibility of integrating genomic profiling in the adult oncology clinic within a community-based, multi-facility, health system. Feasibility is defined as the proportion of patients with successful molecular profiling compared to the number of patients enrolled.	12 months
Secondary	Patient and biopsy characteristics (including cancer type, biopsy type, and number of prior treatments)	Determine patient and biopsy characteristics, including cancer type, biopsy type, and number of prior treatments	12 months
Secondary	Molecular testing characteristics (include: the frequency at which molecular analysis yields a genetic alteration, frequency of actionable alterations, and time from biopsy to final report)	Define molecular testing characteristics.This will include: the frequency at which molecular analysis yields a genetic alteration, frequency of actionable alterations, and time from biopsy to final report.	12 months
Secondary	Molecular profiling influence	Determine how often molecular profiling influences treatment decision.Treatment type implemented will be classified as: standard therapy per treating physician, FDA approved off-label influenced by molecular profiling, internal targeted agent clinical trial influenced by molecular profiling, or external targeted agent clinical trial influenced by molecular profiling.	12 months
Secondary	Clinical outcome of genomic based therapy (response according to RECIST 1.1 response criteria)	Determine the clinical outcome of genomic based therapy, as defined by response rate (according to RECIST 1.1 response criteria) the percent of patients with progression-free survival (PFS) at 4 months, and overall survival.	At 16wks following initiation of treatment impacted by molecular profiling. After 16wks tumor assessments per routine practice/clinical trial protocol requirements, continued until progression/time of treatment discontinuation, whichever is later.